Ya lo_老虎社区_美港股上老虎

Yao84
2021-10-07

Ya lo

Why AbCellera Biologics Stock Jumped 19.4% Last Month

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

Why AbCellera Biologics Stock Jumped 19.4% Last Month

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":823837769,"tweetId":"823837769","gmtCreate":1633610770255,"gmtModify":1633610770498,"author":{"id":3578997581123464,"idStr":"3578997581123464","authorId":3578997581123464,"authorIdStr":"3578997581123464","name":"Yao84","avatar":"https://static.tigerbbs.com/5e30432f9f4a2555514d757fdb9c4f0d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ya lo</p></body></html>","htmlText":"<html><head></head><body><p>Ya lo</p></body></html>","text":"Ya lo","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/823837769","repostId":2173941879,"repostType":4,"repost":{"id":"2173941879","pubTimestamp":1633608180,"share":"https://www.laohu8.com/m/news/2173941879?lang=&edition=full","pubTime":"2021-10-07 20:03","market":"us","language":"en","title":"Why AbCellera Biologics Stock Jumped 19.4% Last Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2173941879","media":"Motley Fool","summary":"Despite last month's gains, the biotech stock is now down roughly 61% year to date.","content":"<h3>What happened</h3>\n<p>Shares of&nbsp;<b><a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> </b>gained 19.4% in September, according to data from S&amp;P Global Market Intelligence. The stock jumped in the middle of the month after the biotech company announced that it had formed a new partnership with <b>Moderna</b> and continued to climb after it detailed another new partnership with Everest Medicines.</p>\n<p><img src=\"https://static.tigerbbs.com/d0c6ec65f7f9b629303bf86d3faa36f2\" tg-width=\"720\" tg-height=\"433\" referrerpolicy=\"no-referrer\"></p>\n<p>ABCL data by YCharts</p>\n<p>AbCellera published a press release on Sept. 15 announcing it had entered into a multi-year collaboration and license agreement with Moderna identify and analyze natural immune system responses to therapeutic antibodies. The company then announced on Sept. 22 that it had secured a 10-year partnership with China-based Everest Medicines for antibody discovery.</p>\n<p><img src=\"https://static.tigerbbs.com/83cc3890e1b1a410d2bc001fb79e9449\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>So what</h3>\n<p>AbCellera has an artificial intelligence powered platform for discovering antibodies and notably helped <b>Eli Lilly</b> develop its bamlanivimab treatment for COVID-19. The new agreement with Moderna outlined six therapeutic antibody targets and will give Moderna the right to commercialize the antibodies resulting from the collaboration. The partnership with Everest is targeting 10 therapeutic antibodies.</p>\n<p>AbCellera typically generates the large majority of its revenue from royalties, so the new partnerships don't necessarily mean that the biotech company will see a major sales windfalls from the collaborations. However, if AbCellera's research yields results that are used in treatments that are brought to market, its sales and earnings could skyrocket.</p>\n<h3>Now what</h3>\n<p>AbCellera Biologics has been losing ground early in October's trading. The company's share price is down roughly 20.8% this month so far.</p>\n<p><img src=\"https://static.tigerbbs.com/a5ffbc18f39cd889c07c75bd57e9f817\" tg-width=\"720\" tg-height=\"433\" referrerpolicy=\"no-referrer\"></p>\n<p>ABCL data by YCharts</p>\n<p>AbCellera now has a market capitalization of roughly $4.3 billion. While the company was able to rise above market momentum in September's trading, it looks like volatility for growth-dependent tech and biotech stocks is catching up to it this month. There doesn't appear to be any business-specific news driving this month's sell-offs, but the current bout of volatility impacting the market suggests that more big swings may be on the horizon.</p>\n<p>AbCellera's analysis and development platform is showing promise, and the fact that the company continues to attract major partnerships is encouraging. However, the company's outlook remains somewhat speculative, and that primes the stock for volatility when turbulence hits the market. For investors looking to benefit from biotech trends, AbCellera has the makings of an appealing long-term investment candidate. However, it's not a low-risk stock, and trading could be bumpy in the near term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why AbCellera Biologics Stock Jumped 19.4% Last Month</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy AbCellera Biologics Stock Jumped 19.4% Last Month\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-07 20:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/07/why-abcellera-biologics-stock-jumped-194-in-septem/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of AbCellera Biologics gained 19.4% in September, according to data from S&P Global Market Intelligence. The stock jumped in the middle of the month after the biotech company ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/07/why-abcellera-biologics-stock-jumped-194-in-septem/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABCL":"AbCellera Biologics"},"source_url":"https://www.fool.com/investing/2021/10/07/why-abcellera-biologics-stock-jumped-194-in-septem/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2173941879","content_text":"What happened\nShares of AbCellera Biologics gained 19.4% in September, according to data from S&P Global Market Intelligence. The stock jumped in the middle of the month after the biotech company announced that it had formed a new partnership with Moderna and continued to climb after it detailed another new partnership with Everest Medicines.\n\nABCL data by YCharts\nAbCellera published a press release on Sept. 15 announcing it had entered into a multi-year collaboration and license agreement with Moderna identify and analyze natural immune system responses to therapeutic antibodies. The company then announced on Sept. 22 that it had secured a 10-year partnership with China-based Everest Medicines for antibody discovery.\n\nImage source: Getty Images.\nSo what\nAbCellera has an artificial intelligence powered platform for discovering antibodies and notably helped Eli Lilly develop its bamlanivimab treatment for COVID-19. The new agreement with Moderna outlined six therapeutic antibody targets and will give Moderna the right to commercialize the antibodies resulting from the collaboration. The partnership with Everest is targeting 10 therapeutic antibodies.\nAbCellera typically generates the large majority of its revenue from royalties, so the new partnerships don't necessarily mean that the biotech company will see a major sales windfalls from the collaborations. However, if AbCellera's research yields results that are used in treatments that are brought to market, its sales and earnings could skyrocket.\nNow what\nAbCellera Biologics has been losing ground early in October's trading. The company's share price is down roughly 20.8% this month so far.\n\nABCL data by YCharts\nAbCellera now has a market capitalization of roughly $4.3 billion. While the company was able to rise above market momentum in September's trading, it looks like volatility for growth-dependent tech and biotech stocks is catching up to it this month. There doesn't appear to be any business-specific news driving this month's sell-offs, but the current bout of volatility impacting the market suggests that more big swings may be on the horizon.\nAbCellera's analysis and development platform is showing promise, and the fact that the company continues to attract major partnerships is encouraging. However, the company's outlook remains somewhat speculative, and that primes the stock for volatility when turbulence hits the market. For investors looking to benefit from biotech trends, AbCellera has the makings of an appealing long-term investment candidate. However, it's not a low-risk stock, and trading could be bumpy in the near term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":816,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Why AbCellera Biologics Stock Jumped 19.4% Last Month

评论（1）

热议股票